Date: 2014-04-14
Type of information: Initiation of the trial
phase: 1-2
Announcement: initiation of the trial
Company: Merck KGaA (Germany)
Product: tepotinib
Action
mechanism: tyrosine kinase inhibitor. Tepotinib is an investigational small-molecule inhibitor of the c-Met receptor tyrosine kinase that has been shown to cause growth inhibition and regression of tumors in preclinical models. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis.
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology
Country: Germany
Trial
details: This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A liver function who have failed sorafenib treatment. (NCT02115373)
Latest
news: * On April 14, 2014, a Phase 1-2 trial sponsored by Merck KGaA was published on the NIH website ClinicalTrials.gov for tepotinib and is currently recruiting participants.
